Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O75140
UPID:
DEPD5_HUMAN
Alternative names:
DEP domain-containing protein 5
Alternative UPACC:
O75140; A6H8V6; A8MPX9; B4DH93; B9EGN9; Q5K3V5; Q5THY9; Q5THZ0; Q5THZ1; Q5THZ3; Q68DR1; Q6MZX3; Q6PEZ1; Q9UGV8; Q9UH13
Background:
GATOR1 complex protein DEPDC5, also known as DEP domain-containing protein 5, plays a pivotal role in the amino acid-sensing branch of the mTORC1 pathway. It functions as an inhibitor, regulating mTORC1 signaling in response to amino acid availability by interacting with small GTPases Rag, thereby controlling their nucleotide loading states.
Therapeutic significance:
DEPDC5 is implicated in Epilepsy, familial focal, with variable foci 1, a condition characterized by focal seizures with variable onset and phenotypic variability within families. Understanding the role of DEPDC5 could open doors to potential therapeutic strategies for this form of epilepsy.